Table S1: Sensitivity analysis, characterizing the impact of various tacrolimus variability definitions on clinical outcomes.

Table S1: Sensitivity analysis, characterizing the impact of various tacrolimus variability

definitions on clinical outcomes.

Tacrolimus CV (%)

Exposure Time Period Definition

African-American NonAfrican-American Graft Loss No Graft

Loss

p

value Graft Loss No Graft

Loss p value Day 0 to End of Follow-Up 53±15 46±15 <0.001 48±14 43±13 <0.001 1 Month to 1 Year 38±22 32±16 <0.001 34±17 30±14 0.0125 1 Month to End of Follow-Up 50±25 36±16 <0.001 41±18 33±15 <0.001 3 Month to 1 Year 42±25 32±19 <0.001 35±25 30±17 0.0441 3 Month to End of Follow Up 54±25 36±21 <0.001 44±26 33±17 <0.001

Tacrolimus CV (%)

Exposure Time Period Definition

African-American NonAfrican-American Acute

Rejection

No Acute Rejection

p value

Acute Rejection

No Acute Rejection

p value Day 0 to End of Follow-Up 53±16 45±13 <0.001 43±12 43±13 0.7303

1 Month to 1 Year 37±23 33±17 0.1096 29±15 31±15 0.3811

1 Month to End of Follow-Up 42±24 33±17 0.0004 32±15 31±15 0.5013

3 Month to 1 Year 45±32 33±21 0.0120 27±13 31±19 0.1852

3 Month to End of Follow Up 50±32 33±21 0.0002 33±15 31±19 0.5463 Tacrolimus CV (%)

Exposure Time Period Definition

African-American NonAfrican-American Late

Rejection

No Late Rejection

p value

Late Rejection

No Late Rejection

p value Day 0 to End of Follow-Up 54±14 46±14 0.0002 45±11 43±13 0.3565

1 Month to 1 Year 36±20 33±18 0.3491 25±12 31±15 0.1189

1 Month to End of Follow-Up 47±21 33±18 <0.001 35±15 31±15 0.2476

3 Month to 1 Year 45±30 33±22 0.0414 27±16 31±19 0.4960

3 Month to End of Follow Up 54±29 34±22 0.0002 39±17 31±19 0.1087 Tacrolimus CV (%)

Exposure Time Period Definition

African-American NonAfrican-American

AMR No AMR p

value AMR No AMR p

value Day 0 to End of Follow-Up 56±27 46±14 0.4206 31±7 43±13 0.0777

1 Month to 1 Year 56±51 33±18 0.3771 19±8 30±15 0.1419

1 Month to End of Follow-Up 61±47 34±18 0.0764 19±7 31±15 0.1216

3 Month to 1 Year 31±21 34±22 0.6253 7±0 31±18 0.1068

3 Month to End of Follow Up 41±17 35±23 0.3206 11±0 31±19 0.1440 Tacrolimus CV (%)

Exposure Time Period Definition

African-American NonAfrican-American Severe

Rejection

No Severe Rejection

p value

Severe Rejection

No Severe Rejection

p value Day 0 to End of Follow-Up 53±19 46±14 0.0018 41±11 43±13 0.5550

1 Month to 1 Year 39±28 33±18 0.3926 29±11 30±15 0.8731

1 Month to End of Follow-Up 42±27 34±18 0.0811 30±11 31±16 0.7829

Table S2: Sensitivity analysis, displaying the impact of various tacrolimus variability definitions on racial disparities for acute rejection and graft loss.

Model

Acute Rejection Graft Loss HR 95% CI p

value HR 95% CI p value

AA Unadjusted Risk 1.68 1.25-2.26 0.001 1.42 1.07-1.88 0.015

Day 0 to End of Follow-Up 1.59 1.19-2.14 0.002 1.27 0.96-1.68 0.100

1 Month to 1 Year 1.47 1.05-2.06 0.026 1.42 1.29-2.35 0.021

3 Month to 1 Year 1.49 0.91-2.42 0.110 1.37 0.94-1.98 0.099

3 Month to End of Follow Up 1.47 0.92-2.33 0.104 1.24 0.90-1.71 0.192

Figure S1: Consort diagram displaying how the final cohort was created.

Figure S2: Estimated acute rejection free survival curves based on tacrolimus variability

(fully adjusted models).

Figure S3: Estimated cumulative incidence of graft loss based on tacrolimus variability

(fully adjusted models).